Controversial report spells doom for EU pharmaceutical parallel trade industry
This article was originally published in SRA
Executive Summary
Should the recommendations of an unashamedly one-sided, recently-released report be taken up by the European Commission’s Directorate General for Enterprise and Industry (DG Enterprise), the pharmaceutical parallel trade industry could cease to exist. The report, published by the consultancy group Europe Economics in May 2008, but only made public by DG Enterprise this month, has resolutely backed calls for a ban on repackaging and relabelling.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: